Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2610-2630
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2610
Table 3 Cox regression with stepwise variable reduction
Dependent: Survival (time, status)

HR (univariable)
HR (multivariable)
AgeMean (SD)1.02 (1.01-1.02, P < 0.001)1.01 (1.01-1.02, P < 0.001)
SexFemale--
Male1.00 (0.93-1.07, P = 0.999)-
RaceWhite--
Black0.91 (0.82-1.02, P = 0.109)0.89 (0.75-1.05, P = 0.165)
Other0.77 (0.71-0.85, P < 0.001)0.84 (0.73-0.96, P = 0.009)
Tumor size< 2--
2-51.27 (1.07-1.52, P = 0.008)1.08 (0.83-1.40, P = 0.558)
> 51.98 (1.66-2.36, P < 0.001)1.41 (1.09-1.82, P = 0.009)
Unknown2.24 (1.86-2.70, P < 0.001)1.69 (1.29-2.22, P < 0.001)
GradeG1/G2--
G3/G41.11 (0.89-1.37, P = 0.348)-
Unknown1.16 (0.90-1.51, P = 0.245)-
Primary siteBody--
Cardia1.16 (1.00-1.35, P = 0.051)1.23 (0.98-1.53, P = 0.071)
Fundus1.07 (0.83-1.38, P = 0.608)1.14 (0.78-1.65, P = 0.503)
Gastric antrum1.11 (0.97-1.26, P = 0.135)1.06 (0.87-1.30, P = 0.551)
Greater curvature1.02 (0.84-1.23, P = 0.878)1.25 (0.96-1.64, P = 0.103)
Lesser curvature0.90 (0.78-1.05, P = 0.190)1.00 (0.79-1.27, P = 0.972)
Pylorus1.07 (0.88-1.30, P = 0.492)1.09 (0.82-1.46, P = 0.545)
Overlapping lesion1.53 (1.32-1.78, P < 0.001)1.38 (1.10-1.73, P = 0.005)
Unknown1.45 (1.24-1.69, P < 0.001)1.34 (1.06-1.69, P = 0.014)
Pathologic stageIB--
IIA1.37 (1.01-1.85, P = 0.045)1.59 (0.98-2.59, P = 0.062)
IIB1.94 (1.44-2.61, P < 0.001)2.37 (1.47-3.84, P < 0.001)
IIIA5.54 (4.14-7.40, P < 0.001)3.41 (2.13-5.44, P < 0.001)
IIIB2.73 (2.05-3.65, P < 0.001)4.86 (3.05-7.76, P < 0.001)
IIIC3.83 (2.87-5.10, P < 0.001)7.42 (4.62-11.92, P < 0.001)
Lymph node countMean (SD)0.99 (0.99-1.00, P < 0.001)0.98 (0.98-0.98, P < 0.001)
Chemotherapy statusNo/unknown-
Yes0.64 (0.59-0.69, P < 0.001)
Radiation statusNo/unknown--
Yes0.63 (0.59-0.68, P < 0.001)0.69 (0.62-0.77, P < 0.001)